George Church

Another glimpse in retrospect. The year 2017 was running, and the second year of the Ph.D. was starting. Our initial deep dive into a single modeling approach expanded to comprise that interconnected levels in biological systems still corresponded to silos-like subdomains in the scientific community. Indeed, there was no modeling approach to rule them all. That is why 𝑴𝒖𝒍𝒕𝒊-𝒍𝒆𝒗𝒆𝒍 𝒂𝒏𝒅 𝒉𝒚𝒃𝒓𝒊𝒅 𝒎𝒐𝒅𝒆𝒍𝒍𝒊𝒏𝒈 𝒂𝒑𝒑𝒓𝒐𝒂𝒄𝒉𝒆𝒔 𝒇𝒐𝒓 𝒔𝒚𝒔𝒕𝒆𝒎𝒔 𝒃𝒊𝒐𝒍𝒐𝒈𝒚 were worth reviewing. That is why, as in many other contexts, it was worth it to comprise and highlight this diversity of perspectives over complexity. 🔗 https://lnkd.in/dRqE7AzX Bardini, R., Politano, G., Benso, A., & Di Carlo, S. (2017). Multi-level and hybrid modelling approaches for systems biology. Computational and structural biotechnology journal, 15, 396-402. Chicago #ComputationalSystemsBiology #multidisciplinarity #interdisciplinarity #modeling #research #science

14

🚀 New Episode Alert on #GrowEverything! This week, Erum Azeez Khan and I were thrilled to welcome @Michael Fischer from @Waterbear and DeSciNYC to explore Decentralized Science (#DeSci). 🧬 Imagine a future where science is not only more collaborative and transparent but genuinely fun. Thanks to DeSci, integrating blockchain technology, this is quickly becoming a reality. In the interview, we discuss how WaterBear is gamifying science through community-driven research projects, even incorporating meme coins to fuel the excitement! *Meme-ified science, what?* 🔍 Curious about how DeSci is accelerating discoveries and making scientific research more inclusive? Join us as we discuss how this innovative approach is reshaping the landscape of scientific exploration. 🎧 Don't miss this great interview: Spotify: https://lnkd.in/gBH_iksJ Apple: https://lnkd.in/gP7TZHyp YouTube: https://lnkd.in/gJYrAe_6 #DecentralizedScience #BlockchainInScience #InnovativeResearch #ScienceCommunity

18

4 Comments

One of the most common misunderstandings in biotech today: the "best" AI automatically delivers the best results.  At DeepMirror, we've discovered a different truth. So many AI tools in biopharma, despite their potential, struggle to find their way into regular use.  Why?  Because having the most advanced algorithms or the largest training datasets doesn't mean that a software is usable. No matter how well a tool performs in theory, if it’s too complex for the end user, it’ll be abandoned.  Our focus is on building AI that scientists can actually use, day in and day out. We prioritize usability, speed, and intuitive design just as much as raw computational power.  As one of our customers put it, "This is the simplest AI software we use." And that's exactly the point. So, when you’re evaluating AI tools, instead of asking, “what makes your AI better than anyone else?”, we think a better question is: “what makes your AI easier to use?”. In the end most AI is like water: The same in every bottle. We've written a brief piece exploring this here: https://lnkd.in/ezkfu3cy Would love to hear your take on this! 

33

4 Comments

❗ One of the things I like most about Aron Knickerbocker is that he isn't hyping the hypable. 🤖 His company, Aulos Bioscience, was the first to put an AI-designed #monoclonalantibody in humans. It would be easy to glorify the #artificialintelligence. ⏩ Instead, he says the IL-2 human mAb Aulos is developing COULD have been designed solely by humans. But, Aulos' humans knew how to use tech to do it faster. 📺 🎧 Get Knickerbocker's pragmatic take on AI in biotech, and learn his secret to building successful biotechs (spoiler: it's all about the data) on this week's episode of the #businessofbiotech. Watch here https://lnkd.in/eur__HP, or listen anywhere you subscribe to podcasts. Life Science Connect Bioprocess Online

29

As I entertain myself with Bayes theory, I found a quote on a project by Solomon Kurz (here: https://lnkd.in/e4CFEzmQ), based on the awesome "Statistical Rethinking" book by Richard McElreath, that exemplifies science in a nutshell: "If we all knew what we were doing, there’d be no need for science." Stay curious. Question everything. Only then can we advance our collective scientific knowledge. #science #computationalbiology #machinelearning #datascience

10

2 Comments

🔫 Ready To Pull The Trigger? 🖇 invest.cytonics.com 🪙 Let us help you make an investment decision by highlighting Cytonics’ achievements and key catalysts in the near future. 🥇 A Track Record Of Excellence As our equity crowdfunding campaign nears its close on May 28 at 11:59 PM PST, Cytonics stands on the brink of transformative growth. We've  advanced through crucial drug development phases, solidifying our position as a leader in regenerative medicine with significant scientific and regulatory achievements. These milestones underscore our transition from a promising biotech startup to a frontrunner in osteoarthritis therapy. With Johnson & Johnson as a notable shareholder and our Phase 1 clinical study progressing towards critical Phase 2 collaborations, we offer a compelling opportunity for investors to engage with a company scaling new heights in medical innovation. This is the most pivotal moment in our Company's 18 year history as we are poised to enter first-in-human human clinical trials. 🤝 Delivering On Promises ✅ Since our last equity crowdfund, we have accomplished every single milestone promised to our investors in our mission of creating the first and only true treatment for osteoarthritis. ✅ Completed GMP manufacturing of lead drug candidate, CYT-108. Completed all preclinical (“IND-enabling”) studies for CYT-108. ✅ Designed the first-in-human Phase 1 clinical trial protocol and submitted to ethics boards for regulatory approval. ✅ Received regulatory approval from AU ethics committees to begin Phase 1 clinical study. ✅ Engaged the Contract Research Organization (Southern Star Research) and clinical sites (Emeritus Research, Novatrials) to conduct the Phase 1 study. ✅ Initiated site initiation visits for Phase 1 human clinical study. ✨ Now, we are on the verge of our most significant drug development milestone to date.  ➡️ We anticipate recruiting our first Phase 1 patient in the next few weeks! ➡️ That patient will be dosed in June 2024. ➡️ We expect our Phase 1 clinical study to complete in June 2025.  ➡️ We will then solicit interest from strategic partners for the Phase 2 clinical trial.  ➡️ A positive Phase 2 dataset will be our catalyst for an exit via IPO or acquisition. ➡️ Johnson & Johnson owns 12% of Cytonics, and will be the first company we approach to discuss an acquisition. ➡️ Alternatively, we may use a positive Phase 2 dataset to access the public markets and raise $100M to fund the final, pivotal Phase 3 clinical trial. 🙌 Ready To Join Us? With over 5,000 shareholders who have invested over $15M over 4 equity crowdfunds, we extend a ❤️ heartfelt thanks to all of our investors for your unwavering belief in our vision. #biotech #biotechnology #arthritis #osteoarthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine #orthopedics #orthopaedics #surgery #investor #FDA #medicine #lifesciences #researchanddevelopment #capitalmarkets #lifestyle

6

Interesting in-depth blog post on PacBio challenges by Keith Robison, well worth a read. My view is broadly similar. Stock is now down 6X since I made my 2024 prediction: (https://lnkd.in/gecsqHTe): "PacBio - Tough spot as again LR market is limited and Oxford Nanopore Technologies is coming at them from below with less expensive instruments so it'll be a battle over a small patch of ground. Hence PacBio buying Omniome, but not clear that it has a SR value proposition that can compete with Illumina (and Element Biosciences)." As Keith points out it's hard to see an M&A deal that would work here even at this low price. IMO private equity isn't going to be interested as they look for good growth potential and that's not showing up; Keith suggests Thermo as a buyer - an interesting idea as they have a decent onco business around Ion Torrent; PACB would give them a more scalable SR technology for liquid biopsy and LR *might* be nice for onco too. Hmmm. Maybe Element or Ultima would be a better fit for them...and much less complex a deal.

48